Krystal Biotech has dosed the first patient in a Phase I/II trial evaluating KB103 for the treatment of dystrophic epidermolysis bullosa (DEB).

The single-centre, open-label, placebo-controlled trial is being conducted at Stanford University, California, US.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial also aims to analyse the safety and tolerability of KB103 in patients with the recessive form of DEB.

Furthermore, it will examine the efficacy of KB103 through wound imaging and analysis of collagen VII expression and anchoring fibril formation in the basement membrane zone.

Krystal Biotech founder and chief operating officer Suma Krishnan said: “This is an important milestone for us, as it brings us a step closer to offering a meaningful therapeutic option for patients with dystrophic epidermolysis bullosa who do not have a treatment option presently.”

“It brings us a step closer to offering a meaningful therapeutic option for patients with dystrophic epidermolysis bullosa who do not have a treatment option presently.”

DEB is a chronic, progressive and extremely painful skin disease caused by mutations in the gene coding for type VII collagen (COL7).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Mutated COL7 makes the DEB patients’ skin incredibly fragile, resulting in blistering or skin loss at the slightest friction.

No approved treatments are currently available for DEB.

KB103 is a replication-defective, non-integrating viral vector that intends to use gene therapy to treat DEB.

It has been developed using Krystal’s STAR-D platform to provide functional human COL7A1 genes directly to the patients’ dividing and non-dividing skin cells.

Last month, KB103 secured an investigational new drug (IND) approval from the US Food and Drug Administration (FDA).